Hemogenyx Pharmaceuticals (LON:HEMO) Trading 1.6% Higher – What’s Next?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded up 1.6% on Thursday . The company traded as high as GBX 699 and last traded at GBX 680. 8,701 shares were traded during mid-day trading, a decline of 71% from the average session volume of 29,849 shares. The stock had previously closed at GBX 669.

Hemogenyx Pharmaceuticals Trading Up 1.6%

The company has a debt-to-equity ratio of 167.66, a current ratio of 1.38 and a quick ratio of 6.72. The business’s 50-day moving average price is GBX 870.57 and its two-hundred day moving average price is GBX 804.82. The company has a market capitalization of £43.69 million, a price-to-earnings ratio of -3.99 and a beta of 1.54.

Hemogenyx Pharmaceuticals (LON:HEMO) last released its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.